21:09 , Apr 27, 2017 |  BC Week In Review  |  Company News

Albany Molecular, Denovo deal

Albany Molecular granted Denovo exclusive, worldwide rights to liafensine (DB104), a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI). Using its biomarker platform, Denovo hopes to analyze previous liafensine trial data and identify patient populations in...
21:55 , Apr 24, 2017 |  BC Extra  |  Company News

Denovo gets rights to depression candidate, seeks biomarkers

Albany Molecular Research Inc. (NASDAQ:AMRI) granted Denovo Biopharma LLC (San Diego, Calif.) exclusive, worldwide rights to liafensine (DB104), a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI). Using its biomarker platform, Denovo hopes to analyze previous...
07:00 , Oct 11, 2016 |  BC Extra  |  Company News

Management tracks

Musculoskeletal company Bone Therapeutics S.A. (Euronext:BOTHE) said CEO Enrico Bastianelli will depart for personal reasons. CBO Thomas Lienard will be interim CEO. Specialty pharma EffRx Pharmaceuticals S.A. (Lausanne, Switzerland) promoted Lorenzo Bosisio to CEO. He...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Broad Institute, Albany Molecular Research deal

The institute granted Albany Molecular non-exclusive rights to IP related to CRISPR- Cas9 . Albany Molecular will use the IP to enhance its drug discovery platform, which it provides as a service to clients and...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Albany Molecular Research, Eagle Pharmaceuticals deal

Eagle and Albany Molecular partnered to develop and commercialize undisclosed products in the U.S. to treat cancer, critical care and Orphan disease. Albany Molecular will provide manufacturing and analytical support for product registration and supply...
01:48 , Sep 24, 2015 |  BC Extra  |  Company News

Management tracks

Drug delivery play leon-nanodrugs GmbH (Munich, Germany) named Theron Odlaug CEO. Odlaug was executive chairman at Cedarburg Hauser Pharmaceuticals Inc. , which Albany Molecular Research Inc. (NASDAQ:AMRI) acquired. Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.)...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Albany Molecular Research, SUNY Poly, PerkinElmer deal

Albany Molecular Research, SUNY Poly and PerkinElmer partnered to establish the Buffalo Medical Innovation and Commercialization (BMIC) Hub. The BMIC Hub, co-located on the Buffalo Niagara Medical Campus, will provide life science discovery services, technology...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kallikrein-related peptidase 5 (KLK5); KLK7; KLK14; suppression of tumorigenicity 14 (ST14; matriptase)

Dermatology INDICATION: Dermatology In vitro and mouse studies have identified coumarin-3-carboxylate-based protease inhibitors that could help treat skin diseases such as Netherton syndrome, which is characterized by high levels of Kallikrein-related protease activity in the...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

Albany Molecular Research management update

Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y.   Business: Supply/Service, Chemistry   Departing: Michael Nolan as SVP and CFO, effective February; he is succeeded by Felicia Ladin, formerly SVP and CFO of global specialty medicines...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Albany Molecular Research, Oso Biopharm deal

Albany Molecular Research completed its acquisition of Oso Biopharm’s Oso Biopharmaceuticals Manufacturing LLC subsidiary for $110 million in cash (see BioCentury, June 9). Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y.   Oso Biopharm Holdings LLC...